Clinical Trial Update: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating afuresertib in combination with paclitaxel for platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Afuresertib (afuresertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Laekna Limited | Conditions: Platinum-resistant Ovarian Cancer | Phase 2 | Status: COMPLETED